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Abstract
Recent work has shown that it is possible to target regulatory elements to DNA sequences of an investigator's 
choosing, increasing the armamentarium for probing gene function. In this review, we discuss the development and 
use of designer zinc finger proteins (ZFPs) as sequence specific tools. While the main focus of this review is to discuss 
the attachment of the FokI nuclease to ZFPs and the ability of the resulting fusion protein (termed zinc finger nucleases 
(ZFNs)) to genomically manipulate a gene of interest, we will also cover the utility of other functional domains, such as 
transcriptional activators and repressors, and highlight how these are being used as discovery and therapeutic tools.
Introduction
The expression repertoire of all the genes in any given cell
is governed by transcriptional activators and repressors
that bind to specific sites in the genome. There are several
protein folds that can elicit sequence specific DNA bind-
ing, including helix-turn-helix, leucine zipper and zinc
finger domains. The C2H2 zinc finger motif, which com-
prises 20 to 30 amino acids containing two Cys and two
His residues coordinated by a zinc atom [1], has proven to
be particularly versatile for protein engineering applica-
tions. An archetypal member of this family is Zif268, also
known as EGR1, which is a transcriptional regulator ini-
tially found in mice. The crystal structure of the mouse
Zif268 three zinc finger peptide bound to its target DNA
sequence showed that the individual zinc fingers fold into
two antiparallel β sheets and an α helix, with the α helix
m a k i n g  s e q u e n c e  s p e c i f i c  D N A  c o n t a c t s  i n  t h e  m a j o r
grove of the DNA [2]. Each zinc finger binds three nucle-
otides, with the entire Zif268 polypeptide binding a nine
base pair (bp) GCG-TGG-GCG DNA motif. Such a mod-
ular design immediately suggested the possibility for
combining zinc fingers with distinct triplet recognition
motifs, to create proteins that could potentially recognize
any DNA sequence. This could include pre-existing zinc
fingers with known triplet binding sequences, as well as
entirely novel designer zinc fingers generated against new
DNA sequences [3,4]. Indeed, even before the crystal
structure and mode of binding was known, systematic
mutations in the α helix of the second zinc finger of the
Sp1 transcription factor had been shown to shift DNA
binding specificity [5]. Moreover, mix and match shuf-
fling of individual zinc fingers was shown to shift DNA
binding specificity towards contiguous triplet DNA
sequences accordingly [6].
Methods for design, testing and implementation of zinc 
finger proteins (ZFPs)
Since the initial proof of concept studies, the design of
highly functional ZFPs has made several significant
advancements. The first generation ZFP design entailed
the use of a modular assembly, in which individual zinc
fingers were optimized against target triplet DNA
sequences, and linked together to form three- or four-
ZFPs against 9 or 12 bp sequences. While modular
assembly provided examples of successfully applied ZFPs,
it was observed that a high failure rate occurred with this
approach [7]. Because this deficiency is likely due to the
influence that neighboring zinc-fingers have on the
sequence specificity of a given zinc finger [8-11], selec-
tion-guided assemblies were developed [12-17]. For
example, Greisman et al described a method to grow zinc
finger modules, using the first two zinc fingers of the
Zif268 trimer against its 6 bp target to anchor a third zinc
finger selected from a phage library using a new 3 bp
sequence as bait.  T h i s  p r o c e s s  w a s  t h e n  r e p e a t e d  t w o
additional times to replace each of the two remaining
Zif268 zinc fingers [12] (Figure 1A). The resulting syn-
thetic zinc finger trimer can display high affinity and
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specificity towards the desired 9 bp target sequence. A
similar concept was employed by Joung et al., who used a
bacterial two hybrid system to optimize zinc finger bind-
ing to DNA sequences of interest [17].
One of the more advanced selection-based design strat-
egies currently in use is referred to as the OPEN (Oli-
gomerized Pool Engineering) design [18,19]. This
approach is an outcome of the Zinc Finger Consortium, a
collaboration across multiple academic labs interested in
promoting the application of ZFPs as a research tool. As
described in detail by Maeder et al. [18], OPEN relies on
an archive of pre-characterized zinc-finger pools that are
organized based on their binding specificity to a given 3
bp sequence. After identifying the desired genomic target
sequence, the appropriate mixtures of zinc-finger pools
are then randomly assembled using overlapping PCR and
screened for the zinc finger assembly displaying the most
potent binding activity to the desired 9 bp target (Figure
1B). A temporary caveat of the OPEN design strategy is
that the archived pools of zinc-fingers do not yet contain
all the possible triplet subsites for a 9 bp target sequence.
Currently, only zinc finger pools for all 16 possible GNN
subsites (where G is a guanine and N is any base), and a
subset of the TNN (where T is a thymine and N is any
base) subsites have been identified [18]. Completing the
zinc finger library for the remaining possible sequence
variables will clearly increase the ability to design ZFPs
against challenging targets.
Another selection-based approach for zinc finger
design utilizes premade bi-partite libraries [14]. The
libraries are composed of two zinc finger pools. In library
one, all the base-contacting positions of the first zinc fin-
ger and some of the second are randomized, while in
library two the remaining base-contacting positions of
the second zinc finger and all the base-contacting posi-
tions of the third are randomized. The remainder of the
Figure 1 Strategies for generation of designer zinc-finger proteins. A. Greisman et al. [12] described the process of growing an artificial zinc-finger 
through the sequential panning of a phage library for each of the three fingers. B. OPEN zinc finger design selects zinc-fingers by screening an archive 
of characterized zinc fingers for each DNA triplet, followed by random PCR assembly and selection of the best assembled zinc finger trimer. C. The 
bipartite design relies on two libraries in which either the first half (library 1) or the second half (library 2) of the Zif268 zinc finger DNA binding residues 
has been randomized.
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zinc finger trimer is the Zif268 sequence in each case.
These libraries are individually screened against a chime-
ric DNA containing the Zif268 target DNA sequence
fused to the DNA sequence of interest. Finally sets of one-
and-a-half zinc fingers are fused together to form pro-
teins that recognize the desired 9 bp target sequence (Fig-
ure 1C). This approach was initially used to construct
three finger ZFPs that bind to sequences within the HIV
promoter [14]. Advantages of the bipartite library screen-
ing approach include the ability to generate DNA targets
beyond the GNN sequence restrictions of earlier meth-
ods. In addition, the overlapping randomization of the
two libraries allows simultaneous screening, greatly
enhancing the speed at which a zinc-finger assembly with
the desired sequence specificity is generated.
More recently, extensive collections of one-finger and
two-finger subunits with known DNA binding specifici-
ties have been mixed and matched to generate individual
four-finger, five-finger and six-finger ZFNs [20]. This
approach, a further extension of the modular assembly
technique, allows the use of ZFPs with longer recognition
sequences, which may afford greater specificity and effi-
cacy.
There remains much debate about the best and most
efficient method for zinc finger design (recently dis-
cussed in [21,22]). While the modular assembly approach
is the quickest and least labor-intensive method to assem-
ble potentially active ZFP trimers, the initial time saving
m a y  b e  o f f s e t  b y  t h e  n u m b e r  o f  p r o t e i n s  r e q u i r e d  t o
screen for functional designs. In contrast, selection based
designs such as the OPEN system involves greater invest-
ment up front, but may generate ZFPs with a higher
probability of functional activity to their intended target
DNA sequences.
Intrinsic to the methods of the above selection-based
designs is the ability to rank the affinities of resulting zinc
finger trimers. The ability to select zinc fingers with the
highest binding affinity has been shown to be important,
a s  t h i s  p r o c e s s  u s u a l l y  a p p e a r s  t o  a l s o  i n c r e a s e  t h e
sequence selectivity [13,16]. Cornu et al demonstrated
that specificity generally inversely correlates with toxicity
[15]. The goal for optimal zinc finger design is to generate
high affinity to intended target, with low affinity to addi-
tional sites in the genome [16]. Toxicities associated with
one class of zinc finger proteins are also discussed below
separately.
Addition of functional domains expands the utility of ZFPs
Designer zinc fingers have been shown to be useful by
multiple approaches. In the simplest application, Choo et
al showed that an artificial three-zinc finger polypeptide
designed against the genomic sequence surrounding the
breakpoint of the oncogenic p190 bcr-abl chromosomal
fusion could decrease RNA levels of the bcr-abl fusion
protein, as well as decrease the viability of cells reliant on
this protein for survival [23]. Excitingly, the utility of
ZFPs can be further expanded through the addition of
functional domains such as transcriptional activation or
repression domains (summarized in Figure 2). For exam-
ple, a sequence-specific transcriptional activator was gen-
erated by fusing two three-finger cassettes to the Herpes
Simplex Virus transcriptional activator protein VP16
[24]. This was shown to be a functional transcriptional
activator when the 18 bp target sequence was incorpo-
rated into a reporter plasmid. Conversely, fusion of the
six-finger protein to the minimal human Kruppel-associ-
ated box-A (KRAB-A) repression domain resulted in a
s t r o n g  d e c r e a s e  i n  r e p o r t e r  g e n e  e x p r e s s i o n  [ 2 4 ] .  T h i s
concept was extended to control endogenous genes. For
example, Beerli et al. [25] fused a six-finger ZFP that rec-
ognizes a unique 18 bp sequence in the 5' untranslated
region of the proto-oncogene Her2 to either the KRAB-A
repression or the VP16 transactivation domains. These
proteins decreased or increased endogenous Her2
expression respectively [25]. The authors further applied
this concept to Her3, targeting an 18 bp motif in the Her3
5' UTR that only differed by three bases from the Her2
sequence. Remarkably, the Her3 specific zinc finger chi-
meras only affected the expression of Her3, and not Her2,
and vice versa. By placing a tetracycline responsive ele-
ment upstream of the zinc finger chimeras and express-
ing in cells together with the tetracycline controlled
transactivator, the expression levels of Her2 could be
placed under the control of doxycycline [25]. Moreover,
the decreased levels of Her2 were shown to have func-
tional consequences, causing cell cycle arrest. Zhang et al
[26] expanded this work, by designing 10 independent
ZFPs fused to the VP16 transactivation domain that rec-
ognize 9 bp sequences within -70 to -860 bps from the
transcriptional start site of the erythropoietin promoter.
This group made the important observation that DNA
binding affinity is not strictly related to the ability to
stimulate transcription, although high affinity interac-
tions are required to see functional effects. Therefore,
chromosomal DNA structure and organization is likely to
restrict access to novel designer zinc fingers.
Additional endogenous genes that have been success-
fully targeted by ZFPs linked to transcriptional activation
domains include VEGF-A [27], PPARγ1 and PPARγ2 [28],
bax  [29] and fushi tarazu (drosophila) [30]. Even the
expression of transgenes driven by strong viral promoters
can be increased using this approach, as demonstrated by
Reik et al. [31]. In this study the authors used DNAseI to
identify accessible regions of chromatin within the SV40
promoter, and generated three-finger ZFPs recognizing
these sites. Using this method, they demonstrated a two-
fold increase in the expression of an IgG transgene driven
by the SV40 transgene in CHO cells [31], an approachDavis and Stokoe BMC Medicine 2010, 8:42
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that could have significant use for increasing the indus-
trial production of therapeutically relevant proteins and
antibodies. A more comprehensive review of the use of
ZFPs to increase or decrease transcription of target genes
can be found in Jamieson et al. [32]. Gene induction using
ZFPs has even been extended to in vivo use in mice, by
infecting mouse ears with adenoviruses containing ZFP-
VP16 fusions targeted to the VEGF-A promoter, resulting
in increased local angiogenesis [33]. Potential therapeutic
uses of ZFPs causing increased VEGF levels are discussed
further in [34].
Some recent advances in the use of inducible systems to
regulate endogenous gene expression using ZFPs have
also been documented. For example, Pollock et al. split
the ZFP DNA binding and VP16 transcriptional activa-
tion domains into two polypeptides separated by an
internal ribosomal entry site (IRES), each fused to either
3xFKBP or mutant FRB domains, using the synthetic
rapamycin derivative AP21967 to induce dimerization.
This approach allowed inducible regulation of VEGF-A
expression from its endogenous locus [35]. Another
approach involved generation of a chimeric protein con-
sisting of a ZFP targeted against the VEGF-A promoter,
the ligand binding domain of the progesterone receptor,
and the p65 NFκB transactivation domain. In the absence
of the progesterone receptor agonist mifepristone, the
ZFP-PR-p65 fusion protein was bound to heat shock pro-
teins in cytosol and was unable to regulate transcription.
Mifepristone addition resulted in dissociation of HSPs,
nuclear translocation and transcriptional activation of
VEGF-A [36].
Finally, in addition to transcriptional activators and
repressors, other regulatory domains can be fused to
ZFPs, allowing additional control of endogenous gene
expression. For example, Snowden et al. [37] fused the
Histone Methyl Transferase Domains of G9A or Suv39H1
to a previously described [27] ZFP targeted to the VEGF-
A promoter. These proteins decreased endogenous
Figure 2 Functional domains attached to zinc finger proteins. This figure presents a summary of the functional domains that have been demon-
strated to be targeted to specific DNA regions by zinc finger proteins. Shown are the structures of the VP16 transactivation domain from the complex 
with PC4 (2PHE), the Kruppel associated box domain (1V65), the histone H3K9 methyl transferase Suv39H1 (2R3A), HhaI DNA methyl transferase 
(1MHT) and FokI endonuclease (1FOK).
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VEGF-A expression, which was associated with increased
lysine-9 methylation of the Histone H3 associated with
the VEGF-A promoter. Repression could be further stim-
ulated by co-expression of an additional ZFP fused to the
v-erbA domain that recruits Histone Deacetylase com-
plexes. Finally, ZFP fusions to DNA methylases have also
been reported, both as an intact methyl transferase fused
to one three-finger ZFP [38], and as two independent
ZFPs fused to methyl transferase fragments that self-
assemble upon colocalization at the correct DNA motif
[39]. While promising, this particular application has not
been demonstrated to apply to single site modification of
complex genomes. Nevertheless, these experiments dem-
onstrate that ZFPs represent powerful tools for precise
modification of chromatin with subsequent control of
local gene expression.
Addition of endonuclease activities to ZFPs to create 
targeted DNA scissors
A further breakthrough in the utility of designer zinc fin-
ger proteins has been the ability to cleave specific sites in
large genomes. The initial proof-of-concept experiment
in this area was the demonstration that the FokI endonu-
clease from the prokaryote Flavobacterium okeanokoites,
can be separated into two functional domains - one that
binds DNA in a sequence specific manner, and one that
cleaves in a sequence independent manner. Moreover, the
cleavage domain can be fused to unrelated DNA recogni-
tion modules and retain DNA cleavage, which occurs at 9
and 13 bps from the recognition site [40]. Structural and
experimental analysis have shown that the nuclease
domain of FokI requires dimerization for endonuclease
activity on the target DNA [41,42]. This fact conveniently
increases the potential specificity for the use of ZFPs
linked to the FokI endonuclease (hereafter termed zinc
finger nucleases, or ZFNs). Therefore by fusing a FokI
monomer to two ZFPs, which bind to adjacent sequences,
will generate at least an 18 bp sequence specific DNA
nuclease that in principle should allow selective targeting
within mammalian genomes. This approach is depicted
in Figure 3, in which two zinc finger trimers are bound to
their cognate DNA sequences creating an active FokI
dimer. The effectiveness of this strategy was initially
shown with artificial DNA substrates in vitro [43] and
integrated transgenes in Xenopus eggs [44]. Subsequently,
advances in the design of ZFPs led to the successful appli-
cations of this technique to endogenous genomic loci in
drosophila [45], human cells [46], plants [47] and C. ele-
gans [48]. The remainder of this review will focus on the
consequences and applications of targeted single
stranded breaks induced by such ZFNs.
Targeted mutations induced by ZFN cleavage
The consequences of a double strand break induced by
targeted ZFN expression vary upon several different fac-
tors, but in general cells repair these breaks by either
non-homologous end joining (NHEJ) or homologous
recombination (HR) (recently reviewed in [49]). The
FokI-mediated DNA cleavage leaves overhanging ends,
which can either be filled in, completely or incompletely,
or chewed back by limited exonuclease activity, followed
by ligation by endogenous DNA ligase activity. In some
cases small regions of single stranded microhomology are
used to initiate strand annealing and ligation. The net
result of this process is that small insertions or deletions
are usually generated in the region flanking the ZFN-
mediated processing. When the ZFPs are targeted to cod-
ing regions, the outcome is often a shift in the reading
frame, usually leading to a null allele of the targeted gene.
Examples of the consequences of ZFN-mediated cleavage
and repair are described in references [50] (drosophila)
and [51] (human). When applied to mammalian cells, this
approach presents an attractive alternative to previous
labor- and time-intensive techniques using homologous
recombination and gene targeting (reviewed in [52]).
Although this has only been tested for a relatively small
number of genes in mammalian cells so far , the results
seem encouraging. An initial proof of concept study was
performed using the dihydrofolate reductase gene
(DHFR) in Chinese hamster ovary (CHO) cells [53].
Using two distinct pairs of ZFNs that show effective tar-
geting of exon 1 of the DHFR gene, CHO cells were trans-
fected with these ZFNs and cloned by limiting dilution.
For the two ZFN pairs in two experiments, 5/68 (7%) and
11/350 (3%) of single cell clones showed alteration of the
target DHFR genes. Culture conditions, the sequence of
the zinc fingers, and the nature of the FokI enzymes likely
contributed to the difference in targeting efficiency
between the two experiments. However, in both experi-
ments approximately 30% of the clones showing DHFR
disruption expressed no wild type (WT) allele, and both
alleles were shown to be independently mutated. Muta-
tions at the DHFR loci were consistent with targeted FokI
cleavage and displayed phenotypic effects expected from
cells lacking functional DHFR [53].
To target a more therapeutically relevant gene, Perez et
al. generated a pair of ZFNs targeted to the first coding
exon of CCR5, the major co-receptor for HIV entry [51].
Using either adenovirus or electroporation, these ZFNs
were introduced into human T cell lines, resulting in
decreased expression of CCR5, as well as protection from
HIV infection. Sequencing clones that proliferated fol-
lowing infection with HIV showed the expected disrup-
tion of the endogenous CCR5 gene, with insertions and
deletions of between 1 and 43 nucleotides following
cleavage and repair. Single cell cloning of 52 individual
infected primary T cells showed that 12 (23%) contained
a modified CCR5  allele; of these, four (33%) clones
showed bi-allelic modification. This approach wasDavis and Stokoe BMC Medicine 2010, 8:42
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extended to a mouse model for HIV infection, where
expansion of the CCR5 modified cells was observed and
corresponded with lower levels of viremia [51]. Based on
these exciting preclinical studies, CCR5  directed ZFNs
are now in phase I human trials to explore their therapeu-
tic value against HIV.
Since these recent reports, additional genes have been
knocked out in mammalian cells using this technique
with similar frequencies and efficiencies. As many as
three genes have been biallelically disrupted in a single
cell line using these reagents either sequentially, or simul-
taneously [54]. These results show the generality of these
methods, as well as their potential for multi-gene analy-
ses.
Gene replacement induced by ZFNs
The second method used by cells to repair damaged DNA
is homologous recombination (HR). This can be favor-
ably exploited in the context of ZFN-mediated cleavage
by introducing exogenously added donor plasmids con-
taining homologous DNA stretches. Initial proof-of-con-
cept experiments in human cells showed the feasibility of
this approach by demonstrating the ability to repair a
mutated form of GFP stably integrated into the genome
[46]. The first example of ZFN-mediated repair of an
endogenous mutated human gene was presented by
Urnov et al. [55]. In this study, the authors designed ZFNs
targeting  IL2Rγ, the gene mutated in X-linked severe
combined immune deficiency (SCID). They used ZFNs
targeted to exon 5 of IL2Rγ, and a plasmid carrying this
exon with a restriction site to monitor incorporation,
flanked by approximately 1 kb homology either side of
the mutation. Co-transfection of ZFNs and this plasmid
into K562 cells showed a 10 to 20% modification rate of
the IL2Rγ exon 5 across a polyclonal cell population, with
similar frequencies documented by limiting dilution
cloning (13/96 (14%) heterozygous clones, of which 6/9
(67%) were homozygous for the introduced mutation).
The authors then introduced a frameshift mutation into
one or both alleles of IL2Rγ using these reagents, thereby
mimicking the defect seen in the human disease, and
finally fixed the mutation using a donor plasmid contain-
ing the wildtype exon. This latter experiment shows the
path for use of this approach in gene therapy. Primary
patient T cells could be extracted and modified ex vivo,
before subsequent re-implantation. A huge benefit of this
approach compared to viral based gene therapy methods,
is the elimination of potential detrimental gene reactiva-
tion events due to insertional mutagenesis [56].
Mouse cells have also been shown to be responsive to
ZFN-mediated genome editing through homologous
recombination. Melanocytes derived from albino mice
contain a point mutation in the first exon of the tyrosi-
nase gene. Cotransfection of these melanocytes with
ZFNs targeting a sequence 80 bps from the Cys85Ser
mutation, together with the WT donor sequence resulted
in pigmented cells as early as four days post-transfection
[57]. Finally, successful genetic modification of mouse ES
cells has also been enabled by ZFNs, which is discussed in
more detail in a later section.
Toxicities associated with ZFNs
While a pair of three-finger ZFNs targeting an 18 bp
sequence should in theory generate a specificity of 7 ×
1010 (greater than the size of the human genome), in prac-
tice more than one site often appears to be cleaved under
these conditions. This is due to the ability of these zinc
fingers to recognize one or two bp variants of the pre-
dicted site, as well as the ability of earlier ZFNs to func-
tion as both homo and heterodimers. As these reagents
are currently being used in clinical trials, it is important
to understand in detail the cause, extent and conse-
Figure 3 Site specific cutting requires heterodimerization of two independently designed ZFNs. Each ZFN binds to at least nine nucleotides 
and flanks a 5 to 6 bp spacer.
5’-GCGTGGGCGgtggccCTAACTCGC - 3’
FokI FokI
5 GCGTGGGCGgtggcc CTAACTCGC 3
3’-C G C A C C C G C caccgg G A T T G A G C G- 5’
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quences of off-target toxicities. Several approaches have
been used to determine the off-target frequency of DNA
cleavage and subsequent toxicity. One of these
approaches simply monitors the presence of the trans-
fected cells over time, looking for cell-intrinsic toxicity
leading to the disappearance of the transfectants. Using
this assay, it was observed that, in general, ZFNs with a
higher affinity to their target site were less toxic than
ZFNs targeting the same site but with lower affinity
[15,16]. The expression levels of ZFNs have also been
shown to correlate with the degree of apoptosis, as mea-
sured by the presence of sub-G1 DNA content [58], while
the use of poorly designed ZFNs have been shown to
increase the level of γH2AX or p53BP1 expression as
compared to optimally designed ZFNs targeting the same
site [16].
Another method for assessing possible off-target cut-
ting is to identify genomic sites that are very similar, but
not identical, to the predicted cutting site. In the study by
Perez et al. using four-finger ZFNs targeted to CCR5, it
was noted that the same region in CCR2 differed by only
2 bps, one per 12 bp zinc finger recognition motif. Detec-
tion of modification at this site, either by a Cel-I nuclease
assay that measures DNA mismatches, or by direct
sequencing of multiple targeted clones, showed a 10-fold
decreased activity at this site relative to CCR5 [51]. An
additional 13 genomic loci that differed from the CCR5
target sequences by 3 bps or less were also identified.
Deep sequencing of these regions following expression of
the CCR5 ZFNs showed only very rare modification (2/
38,023 sequences examined) at one locus, an intron of the
gene ABLIM2. Therefore, this study shows that optimally
designed ZFNs can exhibit very limited off-target cutting.
A recent advance in the design of ZFNs appears to have
significantly decreased the incidence of off-target endo-
nuclease activity. In the original design, either zinc finger
components of the intact ZFN pair could self dimerize to
form the active FokI nuclease, meaning that three puta-
tive genomic sites could be perfect match targets for the
transfected ZFNs rather than just one. In addition, any 1
or 2 bp tolerance with either zinc finger also dramatically
increases the number of potential off-target sites due to
homodimerization (discussed in [59]). Analysis of the
FokI dimer structure identified residues that form the
interface, and suggested mutations that could prevent
homodimerization and therefore allow only heterodi-
merization. Miller et al. [60] showed that mutation of two
amino acids in each dimer partner (E490K/I538K and
Q486E/I499L) dramatically reduces activity as homodim-
ers, but retains the majority of its activity as a heterodi-
mer. A similar approach by Szczepek et al. [61] also
identified pairs of FokI mutants that preferentially acted
as heterodimers. As predicted, these FokI heterodi-
merization mutants show reduced off-target cutting, as
measured by γH2AX and p53BP1 foci [60,61].
Additional reported modifications to the ZFN reagents
to reduce toxicity and off-target cutting include destabi-
lizing the ZFN proteins themselves. This follows from the
observation that high levels expression of ZFNs are toxic
[16,58]. Attaching ubiquitin to the N-terminus of ZFNs
was shown to destabilize these proteins, which could be
overcome by the addition of the proteasome inhibitor
MG132. A second approach utilized fusions to a FK506
Binding Protein (FKBP) domain that is rapidly degraded
unless a rapamycin analogue was added. The authors pro-
pose that these methods generate a higher gene targeting
to toxicity ratio, using viability and p53BP1 staining as
readouts [62].
Application of ZFNs to model organisms
A significant advantage of ZFNs is the ability to geneti-
cally manipulate previously intractable model organisms.
Selective genetic modification has been demonstrated
with the injection of ZFNs into embryos of C. elegans
[48], zebrafish [63-65], drosophila [66] and rat [67]. The
successful application of ZFNs to selectively target a
given gene in these organisms greatly expands their
potential utility and value as models for human disease.
For example, the rat has long been understood to serve as
a valuable model for toxicology and metabolism studies.
However, genetic manipulation of this species has been
hampered by the lack of pluri-potent, germline compe-
tent embryonic stem (ES) cells that can be easily manipu-
lated  in vitro. The ability of ZFNs to bypass the
requirement of ES cells (by direct injection into a single
cell oocyte) has allowed the targeted, heritable mono and
biallelic disruption of a GFP transgene and three endoge-
nous genes (IgM, Rab38 and IL2Rγ) [67,68]. Although it
remains to be demonstrated whether targeted knock-ins
can also be achieved with this approach, selective genetic
deletions will greatly enhance the value of the rat model.
Even for mouse genomic engineering, ZFNs have several
advantages over traditional homologous recombination
approaches: 1. knockouts can be performed in genetic
backgrounds for which ES lines are not available. 2. ZFN
microinjection into oocytes decreases the time to gener-
ate simple knockouts. 3. ZFNs allow the ability to knock-
out a gene in already complex genetic backgrounds where
other mutations have already been established.
In addition to expanding the value of the above model
organisms for human disease research, these models can
also enlighten the mechanism of ZFN-derived genetic
alterations. A recent study using drosophila demon-
strated that DNA repair pathways act on the ZFN
induced double-stranded DNA cuts. Moreover, the
researchers illustrated the ability to bias the outcome ofDavis and Stokoe BMC Medicine 2010, 8:42
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ZFN cuts towards gene replacement (HR) or NHEJ by
manipulating the genes required for each repair pathway
[50]. The rapid rate of successful ZFN application to
numerous organisms, some previously intractable to
genomic manipulation, is quite amazing and suggests this
method of genetic manipulation will soon become a stan-
dard research tool across many disciplines.
Novel uses of ZFNs for future therapeutic applications
Although ZFPs and ZFNs are still a recent area of
research, there are some immediately applicable thera-
peutic opportunities that have arisen. For example,
Sangamo biosciences have developed ZFPs fused to the
VP16 transcriptional activation domain targeted to the
VEGF-A promoter which is currently in Phase 2 trials for
diabetic neuropathy and Amyotrophic Lateral Sclerosis
(ALS). This drug, which involves direct injection of DNA
encoding the ZFPs into the affected site, requires efficient
uptake of the DNA and strong expression in the target
tissues. In addition, ZFNs targeted to the HIV coreceptor
CCR5 (described above) for the treatment of HIV/AIDS
are in Phase 1 Clinical trials. In this approach, patient T
cells are extracted and modified to express the mutant
CCR5 allele which is resistant to HIV infection. While it
is too early to determine the success or failure of this trial,
data from a single patient show that the modified T cells
remain in the blood several weeks after infusion of the
ZFN treated cells http://investor.sangamo.com/
releasedetail.cfm?ReleaseID=247037. Positive selection
for these cells in the patient means that high efficiency
uptake and expression is not critically required. ZFNs tar-
geted to the glucocorticoid receptor introduced into T
cells as a therapy for glioblastoma have also initiated
Phase 1 clinical trials http://investor.sangamo.com/
releasedetail.cfm?ReleaseID=436582.
There are also much earlier stage experiments ongoing
using ZFNs for genomic modification that hold great
promise for future therapeutic opportunities. In particu-
lar, modification of human stem cells using ZFPs and
ZFNs could be used to treat many human diseases. Initial
experiments in mouse embryonic stem cells showed that
ZFPs fused to transcriptional activator or repressor
domains could modify the Oct4 locus, and uncovered an
unexpected paradoxical role this gene serves in maintain-
ing pluripotency. In these studies, the repressor ZFP was
shown to induce the expected differentiation, while the
activator ZFP also surprisingly caused some cell differen-
tiation [69]. Use of ZFNs has also been extended to
human ES cells [70]. Hockemeyer et al applied ZFNs to
introduce GFP into the Oct4 locus allowing the fluores-
cent tagging of cells depending on their differentiation
status. In addition, the authors used ZFNs to target the
first intron of the PPP1R12C  gene using homologous
recombination. The authors used both the endogenous
PPP1R12C  promoter as well as the phosphoglycerol
kinase (PGK) promoter to drive expression of puromycin
resistance. Interestingly, the targeting efficiencies in both
cases were quite similar (approximately 50%), with a sim-
ilar degree (approximately 50%) of non-targeted integra-
tion in both cases. Targeting of non-expressed genes was
also shown by successfully targeting PITX3, a gene that is
not expressed in hES cells. Gene repair and gene knock-
out have also been demonstrated in induced pluripotent
stem (iPS) cells [71]. Importantly, experiments performed
in all of the above studies show that ZFN modified hES
cells retain proliferative capacity and pluripotency, open-
ing the door to modification of disease-related genes in
affected individuals.
In some diseases, it is not genomic DNA that is altered,
but mitochondrial DNA. Neurogenic muscle weakness,
ataxia, and retinitis pigmentosa (NARP) and maternally
inherited Leigh's syndrome are caused by a single
T8993G nucleotide alteration in mitochondrial DNA
[72]. A combination of adding a nuclear exclusion
sequence and a mitochondrial targeting sequence was
shown to be effective in localizing ZFNs to the mitochon-
dria [73]. However, the conventional heterodimeric ZFNs
were unsuccessful at binding and/or cleaving the appro-
priate site in the mitochondrial genome. Therefore Minc-
zuk  et al [72] developed a novel single ZFN which
expresses two Fok1 proteins separated by a flexible linker,
using ZFPs to direct this polypeptide to the T8993G
mutation. When expressed in cells expressing copies of
both the mutant and WT mitochondrial genome, this
quasi-dimeric  ZFN was able to selectively cleave the
m u t a n t  c o p y  l e a d i n g  t o  e n r i c h m e n t  o f  t h e  W T  c o p y ,
which could be sufficient to reverse phenotypic conse-
quences.
In addition to their use as direct therapeutics, ZFNs can
also aid in the drug discovery and/or drug manufacturing
process. Chinese hamster ovary (CHO) cells are used to
produce many different recombinant proteins for ther-
apy. Cost et al [74] describe the use of ZFNs to delete Bax
and Bak from CHO cells, making these cells more resis-
tant to apoptosis induced by stresses as a result of growth
in large bioreactors. Double knockout cells were obtained
by sequentially transfecting CHO cells with BAK ZFNs
(2/552 cell clones (0.3%) showed modification of both
alleles) followed by BAX ZFNs (21/79 clones (26%)
showed deletion of BAX, which is fortuitously hemizy-
gous in this cell line). Double mutant cells were almost
completely resistant to apoptosis, and showed a two- to
five-fold increase in recombinant antibody production
under stressed conditions [74].
Finally, ZFPs and ZFNs can also aid the drug discovery
process by creating isogenic lines that vary only by the
presence or absence of the drug target of interest. For
example Liu et al. [75] used ZFPs targeting the parathy-Davis and Stokoe BMC Medicine 2010, 8:42
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roid hormone receptor (PTHR) fused to a transcriptional
activation domain, to elevate levels of PTHR in 293 cells
which normally do not express this protein, as well as
fused to a transcriptional repressor domain to repress
expression in SAOS2 cells. Such cell lines create an
almost perfect method to discriminate on-target from
off-target effects of a given drug.
Conclusions
Manipulating endogenous genes at will has long been the
goal for researchers wishing to understand and treat
human diseases. The use of engineered zinc fingers to
modify specific genomic loci is a relatively recent addi-
tion to this area, but is rapidly showing enormous prom-
ise at becoming a reliable research and therapeutic tool.
In fact, designer ZFPs are already in clinical trials, and a
multitude of others are in development. However, there
are a few cautions that prevent unbridled enthusiasm at
this time and point to the need for further technical
development. For example, it is clear that some regions of
the genome are more targetable than others by ZFPs; the
reason for this is not completely clear, and until this is
resolved, progress will remain somewhat impeded. In
addition, the potential toxicities as a result of off-target
binding and cutting (in the case of ZFNs) are still not
completely understood, and the methods currently avail-
able to even monitor these events are laborious. While
Z F N s  h a v e  b e e n  s u c c e s s f u l l y  e m p l o y e d  i n  n u m e r o u s
model organisms to generate gene knock-outs, the ability
of ZFNs to enhance the generation of knock-in animals
remains largely untested. Finally, the expansion of thera-
peutic ZFPs will also be limited by the ability to efficiently
deliver the ZFP into the disease relevant cell. Neverthe-
less, given the explosive progress made in just the last 10
to 15 years, one cannot help but be excited about what
will happen in the next equivalent time period.
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